“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy” Read more
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma Read more
A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy Read more
A Phase 2 Study To Assess The Efficacy And Safety Of TGR-1202 (Umbralisib) Monotherapy In Patients With Non-Follicular Indolent Non-Hodgkin?S Lymphoma Read more
A Phase 2 Study To Assess The Efficacy And Safety Of Ublituximab And Umbralisib In Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib Or Venetoclax Read more
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies Read more
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma Read more
A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies Read more
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study Of Bendamustine And Rituximab (BR) Alone Versus In Combination With Acalabrutinib (ACP 196) In Subjects With Previously Untreated Mantle Cell Lymphoma Read more
